Psychopharmacologic Drugs Panel Renewal

Federal Register notice: FDA is announcing the renewal of its Psychopharmacologic Drugs Advisory Committee for an additional two years beyond the charter expiration date. The new charter will be in effect until 6/4/2026. To view the notice, click here.

Read more